The interaction of PD-1 with its ligands, PD-L1 and PD-L2, on tumor-infiltrating lymphocytes (TILs) is widely regarded as a critical mechanism for tumor immune evasion, making it a crucial therapeutic target. The gene discussed is PDCD1LG2; the disease is neoplasm.